CAR-NK (AB-201)

About Artiva Biotherapeutics

Artiva Biotherapeutics is advancing a scalable, allogeneic NK cell therapy platform to overcome the toxicity, cost, and manufacturing limitations of current cell therapies. Its lead program, AlloNK, is in multiple Phase 1/2 trials for autoimmune diseases and B-cell malignancies, leveraging a unique combination approach with monoclonal antibodies. The company's strategy is built on a manufacturing-first approach, enabled by a strategic partnership with GC Cell, aiming to deliver safe, effective, and accessible treatments.

Therapeutic Areas

Other HER2+ Solid Tumors Drugs